protac brd-4 degrader-2

PROTAC BRD4 Degrader-2 is an efficacious degrader of PROTAC BRD4(BRD4 BD1,IC50 of 14.2 nM).

PROTAC BRD4 Degrader-29 (compound 7a) is a potent BRD4 PROTAC degrader with a DC50 of 89.4 nM, playing a significant role in cancer research.

PROTAC BRD4 Degrader-28 (Compound 4) is a PROTAC degrader specifically targeting BRD4, and it holds potential for cancer research.

PROTAC BRD4 Degrader-23 (compound 17) is an effective visible light-controlled degrader. When exposed to 405 nm light, it can inhibit the proliferation of tumor cells.

PROTACBRD4 Degrader-26 (PROTAC-2) is a photo-regulated PROTAC designed to degrade BRD4, achieving 80% degradation efficiency at a concentration of 1 μM. This compound can be inactivated by ultraviolet light.

PROTAC BRD4 Degrader-21 (Comp 74), a potent BRD4 degrader, has shown significant inhibition of tumor growth in mouse xenograft models, indicating its potential for anticancer research [1].

PROTAC BRD4 Degrader-22 (Compd 44h) is a PROTAC-based degrader targeting BRD4, with a pDC50 of 9.2 in MOLT4 cells over 24 hours [1].

PROTAC BRD4 Degrader-20 (compound 195) is a bifunctional degrader of BRD4 [1].

PROTAC BRD4 Degrader-25 (Compound 1-f), a targeted BRD4 degrader, is utilized in the study of cancer and additional diseases related to bromodomains [1].

PROTAC BRD4 Degrader-27 is a selective PROTAC targeting BRD4, distinguished from BRD2/BRD3. This compound is composed of the E3 ubiquitinase ligand Thalidomide-4-OH, the PROTAC Linker γ-Aminobutyric acid, and the PROTAC target protein ligand PROTAC BRD4 ligand-3. The active control for this target protein ligand is Mivebresib, while the conjugate of the E3 ubiquitin ligase ligand and Linker is identified as Pomalidomide 4'-alkylC3-acid.